Platelet autologous plasma in post-traumatic knee osteoarthritis treatment

Havryliuk, H.; Khimion, L.

doi:10.1016/j.jcot.2018.08.007

Cited by 7 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTOA is characterized by an acute injury-induced joint inflammation followed by a gradual degradation of articular cartilage joints. 2,3 Currently, there is no FDA-approved disease-modifying osteoarthritis drug, and the final treatment of OA is joint replacement. 6 Compared to parenteral administration, oral route typically causes neither tissue damage nor pain and requires less patient supervision and cost of care.…”

Section: Discussionmentioning

confidence: 99%

“…1 PTOA is characterized by an acute injury-induced joint inflammation followed by a gradual degradation of articular cartilage joint. 2,3 Anterior cruciate ligament and meniscus surgery may restore joint function but does not affect PTOA pathogenesis. 4,5 There is no FDA-approved disease-modifying osteoarthritis drug for prevention and treatment of PTOA.…”

Section: Introductionmentioning

confidence: 99%

“…10 Furthermore, administration of IL-1RA requires intra-articular injection. 2 Such injection with short intervals is not practical for managing a long-term degenerative disease such as PTOA. Gene therapy using IL-1RA has shown its promise, but it requires viral vectors for delivery, and a clinical trial to assess its safety is underway.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

Zhang

Hang

Feng

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

Post-traumatic osteoarthritis is a prevalent debilitating joint disease. However, there is no FDA-approved disease-modifying osteoarthritis drug currently. Gene therapy can improve disease progression but lacks an effective delivery system. Here, we constructed an oral drug delivery system by non-virusmediated interleukin-1b (IL-1b) short hairpin RNA (shRNA) and non-pathogenic yeast to evaluate its effect on osteoarthritis therapy. After recombinant IL-1b shRNA/yeast therapy, yeast microcapsule-mediated oral delivery of IL-1b shRNA greatly reduced the IL-1b expression in intestine macrophage, bone marrow macrophage, and articular cartilage, systematically regulate the inflammatory response. The degeneration of articular cartilage was significantly inhibited in the medial femoral condyle and medial tibial plateau of the knee joint. And the expression of osteoarthritis markers Col X and MMP13 was reduced in the knee joint. Thus, yeast microcapsule-mediated oral delivery of IL-1b shRNA may serve as a novel gene therapy strategy for treating joint degeneration through immunomodulation of the mononuclear phagocyte system from the intestine to subchondral bone marrow and ultimately preserving the articular cartilage joint.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

Zhang

Hang

Feng

et al. 2021

Molecular Therapy - Nucleic Acids

View full text Add to dashboard Cite

show abstract

“…Post-traumatic osteoarthritis (PTOA) is characterized by an acute injury-induced joint inflammation followed by a gradual degradation of articular cartilage 1 , 2 . Almost fifteen percent of the global population over 60 years suffers from PTOA 3 and whose further development will lead to disability.…”

Section: Introductionmentioning

confidence: 99%

Yeast Cell wall Particle mediated Nanotube-RNA delivery system loaded with miR365 Antagomir for Post-traumatic Osteoarthritis Therapy via Oral Route

Zhang¹,

Hang²,

Zhang³

et al. 2020

Theranostics

View full text Add to dashboard Cite

Post-traumatic osteoarthritis (PTOA) is an acute injury-induced joint inflammation followed by a gradual degradation of articular cartilage. However, there is no FDA-approved Disease-Modifying Osteoarthritis Drug currently. Although gene therapy with microRNA can improve PTOA progression, there is no effective gene delivery vehicle for orally deliver therapeutics due to the harsh environment of the gastrointestinal tract. In this study, we investigated the effect of yeast cell wall particle (YCWP) mediated nanotube-RNA delivery system on PTOA therapy via oral route. Methods: Nontoxic and degradable AAT and miRNA365 antagomir was self-assembled into miR365 antagomir/AAT (NPs). Then NPs-YCWP oral drug delivery system was constructed by using NPs and non-pathogenic YCWP which can be specifically recognized by macrophages. Moreover, surgical destabilization of the medial meniscus induced PTOA mice model was established to evaluate the therapeutic effect of NPs-YCWP via oral route. Results: Compared with control group, NPs showed higher gene inhibition efficiency both in chondrogenic cell line and primary chondrocytes in vitro . Treatment of macrophages with fluorescently labeled NPs-YCWP, the results showed that NPs-YCWP was successfully engulfed by macrophages and participated in the regulation of gene expression in vitro . Under the protection of YCWP, miR365 antagomir/AAT passes through the gastrointestinal tract without degradation after oral administration. After NPs-YCWP therapy, the results of histological staining, gene and protein expression showed that miR365 antagomir/NPs-YCWP improved the symptom of PTOA. Conclusion: Here, we constructed a biodegradable drug delivery system based on non-pathogenic YCWP and nanotubes, which can be used for PTOA therapy via the oral route. It suggests a new gene therapy strategy with YCWP mediated oral nano drug delivery system may serve as a platform for joint degeneration treatment.

show abstract

“…The incidence rate of PTOA is also increasing (4). At present, the early diagnosis of PTOA is diffi� cult (5). Due to a lack of specific interventions, PTOA seriously affects the daily life of patients (6).…”

Section: Introductionmentioning

confidence: 99%

Reduced miR‑519d‑3p levels in the synovium and synovial fluid facilitate the progression of post‑traumatic osteoarthritis by targeting VEGF

Gao

Xia

2021

Exp Ther Med

View full text Add to dashboard Cite

T�� T�� sion and clinical significance of miR-519d-3p in patients with post-traumatic osteoarthritis (PTOA). The levels of miR-519d-3p in the synovium and synovial fluid (SF) of all subjects were detected by reverse transcription-quantitative polymerase chain reaction. The results of the present study demonstrated that the levels of miR-519d-3p in the synovium and SF of patients with PTOA were significantly lower, but that the VEGF content was significantly higher, compared with that of control group. Dual-luciferase reporter and Western blot assays demonstrated that VEGF was a target gene of miR-519d-3p. Furthermore, miR-519d-3p inhibitor-induced cell apoptosis, and cell cycle arrest could be partially reversed by silencing VEGF. Additionally, the level of miR-519d-3p in the synovium and SF of patients with PTOA was negatively correlated with the level of VEGF. ROC analysis demonstrated that miR-519d-3p levels in the synovium and SF could effectively differentiate patients with PTOA from healthy controls, with areas under the ROC curve of 0.928 and 0.896, respectively. In conclusion, reduction of miR-519d-3p in the synovium and SF resulted in the upregu� lation of VEGF in patients with PTOA, and miR-519d-3p may be a potential therapeutic target of PTOA.

show abstract

Platelet autologous plasma in post-traumatic knee osteoarthritis treatment

Cited by 7 publications

References 6 publications

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

Yeast microcapsule-mediated oral delivery of IL-1β shRNA for post-traumatic osteoarthritis therapy

Yeast Cell wall Particle mediated Nanotube-RNA delivery system loaded with miR365 Antagomir for Post-traumatic Osteoarthritis Therapy via Oral Route

Reduced miR‑519d‑3p levels in the synovium and synovial fluid facilitate the progression of post‑traumatic osteoarthritis by targeting VEGF

Contact Info

Product

Resources

About